| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T369 |
0-20 |
Sentence |
denotes |
Question 2 statement |
| T370 |
21-151 |
Sentence |
denotes |
At the present time, evidence from the first published RCT does not support off-label treatment with LPV/RTV in COVID-19 patients. |
| T371 |
152-296 |
Sentence |
denotes |
This result should also discourage the use of other protease inhibitors (e.g. darunavir), at least until results of dedicated RCT are available. |
| T372 |
297-529 |
Sentence |
denotes |
Although promising in preclinical studies, remdesivir should be currently provided for treating COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature. |
| T373 |
530-711 |
Sentence |
denotes |
Pending high-level supporting evidence, favipiravir and umifenovir should not be provided outside RCT, at least in those countries where they are not approved for other indications. |
| T374 |
712-819 |
Sentence |
denotes |
Oseltamivir or zanamivir should be provided only in the presence of suspected/proven concomitant influenza. |
